title: Drug-induced tolerance to allografts in mice. XII. The relationships between tolerance, chimerism, and graft-versus-host disease.
abstract: When AKR/J Sea (AKR, H-2k) mice were primed i.v. with 1 X 10(8) viable spleen cells from naive C3H/He Slc (C3H, H-2k) mice and treated i.p. with 200 mg/kg cyclophosphamide (CP) 2 days later, a minimal degree of mixed chimerism associated with tolerance to C3H skin was established without graft-versus-host disease (GVHD) and maintained for at least one month. When AKR mice were primed i.v. with 1 X 10(8) viable spleen cells from C3H mice preimmunized i.v. 7 days earlier with 5 X 10(7) viable AKR spleen cells, and treated with 200 mg/kg CP, chimerism became exclusive, but lethal GVHD occurred in the AKR mice. Moreover, most of normal AKR mice primed with the preimmunized C3H spleen cells without CP died of GVHD. In contrast, in a major histocompatibility complex (MHC)-incompatible combination of AKR (H-2k)-C57BL/6 Cr Slc (B6, H-2b), mixed chimerism, tolerance to skin allografts, and GVHD were not observed, whether or not the mice had been treated with naive or preimmunized B6 spleen cells with or without CP.
authors.forename: H
authors.initials: H
authors.lastname: Mayumi
authors.forename: K
authors.initials: K
authors.lastname: Himeno
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: N
authors.initials: N
authors.lastname: Tokuda
authors.forename: J L
authors.initials: JL
authors.lastname: Fan
authors.forename: K
authors.initials: K
authors.lastname: Nomoto
mesh_terms: D000818:Animals; D001835:Body Weight; D002678:Chimera / Q000187:drug effects; D003520:Cyclophosphamide / Q000494:pharmacology; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D008285:Major Histocompatibility Complex; D051379:Mice; D008815:Mice, Inbred Strains; D016038:Skin Transplantation; D013154:Spleen / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D003520:Cyclophosphamide